Although fluvoxamine has shown promise in preventing COVID-19 progression as an early treatment option in several clinical trials, the specific contribution of fluvoxamine’s Sig-1R agonism to the advantageous effects observed in patients with SARS-CoV-2 infection remains to be established. This evidence concerns the gene SIGMAR1 and COVID-19.